A Multicenter, Open-Label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-Daily Darunavir Versus Atazanavir in HIV-Infected Treatment-Naive Adult Patients.

Trial Profile

A Multicenter, Open-Label, Randomized Study to Assess the Metabolics, Efficacy, and Safety of Once-Daily Darunavir Versus Atazanavir in HIV-Infected Treatment-Naive Adult Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2016

At a glance

  • Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms METABOLIK
  • Sponsors Tibotec Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Feb 2016 Results of substudy published in the HIV Clinical Trials
    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top